Fixed-dose combination: beware of its limitations

NEELESH GUPTA,1 MOHAMMED ELKHAZENDAR,2 RAJEEV GUPTA3

1 Department of Medicine, Nazareth Hospital, Philadelphia, PA, USA
2 Clinical Sciences Department, College of Medicine, University of Sharjah, United Arab Emirates
3 Department of Cardiology, Mediclinic Al Jowhara Hospital, Al Ain, United Arab Emirates

We welcome correspondence and research letters to the journal. Research letters should be no more than 800 words with a maximum of 10 references, one table and/or one figure. These will usually be short reports of interim work or final reports of research that do not warrant a full research paper publication.

Letters to the editor relating to any articles published in the Journal - Letters should ideally be submitted within 2 months following publication of the article on which the authors wish to comment, and should be no more than 600 words with up to 5 references.

We read with great interest the editorial detailing the likelihood of cardiovascular (CV) benefit from the triple fixed-dose combination (FDC) therapy for patients with type 2 diabetes mellitus.1 Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are preferred in view of their documented CV benefits. The FDC pill containing metformin, dipeptidyl peptidase-4 (DPP-4) inhibitor and SGLT2i has been approved by the US FDA. However, the CV protective effects of SGLT2i may be less when combined with metformin. For instance, with canagliflozin, the risk of CV death and hospitalisation was reduced by 36% in metformin non-users versus 12% in metformin users (p=0.03).2 Although this may well be a type 1 statistical error, notably, a similar trend was also observed with empagliflozin (53% vs 32%, p=0.01).3 A possible explanation may be that the use of metformin has its well-documented CV benefits; thus, additional benefits were minimised with the added use of SGLT2i.4 Interestingly, the addition of a DPP-4 inhibitor to metformin resulted in improved CV outcomes compared with the initiation of DPP-4 inhibitor in non-metformin users.5 Therefore, the issue deserves further investigation, perhaps as an endpoint in a future CV outcome trial with an SGLT2i.

Conflicts of interest None.

Funding None.

References

Correspondence: Dr Mohammed Elkhazendar
Clinical Sciences Department, College of Medicine, University of Sharjah, United Arab Emirates
E-mail: modnnkh@yahoo.com

Br J Diabetes 2021;21:ONLINE AHEAD OF PUBLICATION